We are live on ! Find out more

ESPR

Esperion Therapeutics

ESPR

Market cap $819M

Delisted

ESPR was delisted on the 10th of July, 2026.

Back to rankings

About: Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Employees: 294

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger

Stockholders of Esperion Therapeutics NASDAQ: ESPR approved the company's merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to remarks delivered during the meeting.

Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is se.

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults – ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associated an enhanced LDL-C lowering with bempedoic acid.

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Zacks Investment Research

ESPR Stock Surges 44% in a Month: Here's What You Need to Know

Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.

ESPR Stock Surges 44% in a Month: Here's What You Need to Know

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH) Congruent with Reductions in Adult Exposures – – New Analyses from CLEAR Outcomes Trial Identified Factors Associated With Enhanced LDL-C Reductions in Adult Patients – ANN ARBOR, Mich., May 13, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two new abstracts and three encore abstracts have been accepted for presentation at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27, 2026, in Athens, Greece.

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is se.

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Esperion Therapeutics, Inc. (NASDAQ: ESPR ) related to its sale to funds managed by ARCHIMED. Under the terms of the proposed transaction, Esperion shareholders are expected to receive $3.16 per share in cash and the right to participate in contingent milestone payments. Is it a fair deal?

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, May 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Esperion (NASDAQ: ESPR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with ARCHIMED. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

See News Rankings

Price charts implemented using Lightweight Charts™